TY  - JOUR

T1  - The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

JO  - Trials

UR  - http://eprints.whiterose.ac.uk/142352/

PY  - 2018/12/01

AU  - Striha A

AU  - Ashcroft AJ

AU  - Hockaday A

AU  - Cairns DA

AU  - Boardman K

AU  - Jacques G

AU  - Williams C

AU  - Snowden JA

AU  - Garg M

AU  - Cavenagh J

AU  - Yong K et al

ED  - 

DO  - DOI: 10.1186/s13063-018-2524-8

PB  - Springer Nature

VL  - 19

IS  - 1

Y2  - 2025/01/13

ER  -